Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 67 of 151

  1. IMGN151-1001

    AbbVie Deutschland GmbH & Co. KG

    Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer

    phase 2 small molecule active

    1 trial

  2. IMGN632-0802

    AbbVie Deutschland GmbH & Co. KG

    CD123 positive Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  3. IMGN853-0424

    AbbVie Deutschland GmbH & Co. KG

    Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

    phase 2 small molecule active

    1 trial

  4. IMLIFIDASE

    The George Institute

    kidney trasplant

    phase 2 small molecule active

    1 trial

  5. IMMU-132-06

    Gilead Sciences Pty Limited

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  6. IMMUWHY

    The George Institute

    Advanced stage intrahepatic biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  7. IMMUWIN

    The George Institute

    Intermediate stage hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  8. IMP1734

    Eikon Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  9. IMX-110 combined with Tislelizumab

    Immix Biopharma

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  10. IN10018

    Hospital Authority, Hong Kong

    Cervical Adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. INAVOLISIB

    Fondazione Telethon ETS

    endometrial cancer

    phase 2 small molecule active

    1 trial

  12. INBRX-101 Concentrate for Solution for Infusion 50mg/ml

    Sanofi-aventis Healthcare Pty Ltd

    Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

    phase 2 small molecule active

    1 trial

  13. INBRX-106 - Hexavalent OX40 agonist antibody

    Inhibrx Biosciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  14. INBRX-109

    Inhibrx Biosciences

    Conventional Chondrosarcoma

    phase 2 small molecule active

    1 trial

  15. INBRX101-01-201

    Sanofi-aventis Healthcare Pty Ltd

    Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

    phase 2 small molecule active

    1 trial

  16. INC280

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  17. INCA34176-254

    Incyte

    chronic graft-versus-host disease

    phase 2 small molecule active

    1 trial

  18. INCAGN 2385-203

    Incyte

    In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.

    phase 2 small molecule active

    1 trial

  19. INCB 00928-104

    Incyte

    Anaemia associated with myelofibrosis

    phase 2 other active

    1 trial

  20. INCB 54707-208

    Incyte

    Treatment of patients with inadequately controlled moderate to severe asthma

    phase 2 small molecule active

    1 trial

  21. INCB 84344-102

    Incyte

    Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors

    phase 2 small molecule active

    1 trial

  22. INCB000928, Placebo

    Incyte

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule active

    1 trial

  23. INCB099280, Adagrasib

    Incyte

    Advanced Solid Tumors Harboring a KRASG12C Mutation

    phase 2 small molecule active

    1 trial

  24. INCB123667-203

    Incyte

    Ovarian Cancer

    phase 2 other active

    1 trial

  25. INCIPIT

    Verona Pharma Ireland Limited

    multifocal spasticity of the upper and lower limb due to cerebral palsy

    phase 2 small molecule active

    1 trial

  26. INCMGA0012-204

    Incyte

    Endometrial cancer, Endometrial cancer

    phase 2 small molecule active

    1 trial

  27. INDOCYANINE GREEN

    The George Institute

    Patients with primary invasive early breast cancer (T1-T2) that will undergo planned breast-conserving surgery

    phase 2 small molecule active

    1 trial

  28. INDOCYANINE GREEN

    Fondazione Telethon ETS

    Patients with gynecological cancers undergoing pelvic exenteration

    phase 2 small molecule active

    1 trial

  29. INDV-2000

    Indivior Pty Ltd

    Opioid Use Disorder

    phase 2 small molecule completed

    1 trial

  30. INDV-6001

    Indivior Pty Ltd

    Moderate to Severe Opioid Use Disorder

    phase 2 small molecule completed

    1 trial

  31. INEBILIZUMAB

    Elan Pharma International

    Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])

    phase 2 small molecule active

    1 trial

  32. INES

    Fondazione Telethon ETS

    Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  33. INF904

    InflaRx GmbH

    Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to Severe Hidradenitis Suppurativa (HS)

    phase 2 small molecule active

    1 trial

  34. INM-755 (cannabinol) cream

    InMed Pharmaceuticals

    Epidermolysis Bullosa Simplex

    phase 2 small molecule completed

    1 trial

  35. INO-3107

    INOVIO PHARMACEUTICALS, INC.

    Respiratory Papillomatosis

    phase 2 small molecule completed

    1 trial

  36. INO-3112

    INOVIO PHARMACEUTICALS, INC.

    Cervical Cancer

    phase 2 mab completed

    1 trial

  37. INO-3112

    INOVIO PHARMACEUTICALS, INC.

    Head and Neck Squamous Cell Cancer

    phase 2 mab completed

    1 trial

  38. INO-3112 vaccine

    INOVIO PHARMACEUTICALS, INC.

    Uterine Cervical Neoplasms

    phase 2 mab terminated

    1 trial

  39. INO-4700

    INOVIO PHARMACEUTICALS, INC.

    Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

    phase 2 small molecule completed

    1 trial

  40. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    Glioblastoma

    phase 2 mab active

    1 trial

  41. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    Urothelial Carcinoma

    phase 2 mab completed

    1 trial

  42. INS1007-231

    Insmed Limited

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  43. INS1009-202

    Insmed Limited

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial

  44. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Breast Cancer

    phase 2 small molecule active

    2 trials

  45. INXN-2001

    Alaunos Therapeutics

    Melanoma

    phase 2 mab completed

    1 trial

  46. INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) Deficiency, Generalized Arterial Calcification of Infancy (GACI), Pseudoxanthoma elasticum (PXE)

    phase 2 small molecule active

    1 trial

  47. IO102

    IO Biotech

    NSCLC

    phase 2 mab completed

    1 trial

  48. IO102-IO103

    IO Biotech

    Melanoma

    phase 2 small molecule active

    2 trials

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.